Justin leads the overall technological and scientific strategy for Avectas and its Solupore® technology. Solupore® utilizes a non-viral, physiochemical transfection process which enables complex, multi-step editing for the production of next-generation cell therapy products. Prior to joining Avectas, Justin was the Vice President of Technical Operations at Repertoire Immune Medicines where he led CMC development and clinical manufacturing of their multi-targeted antigen-specific T-cell platform. Justin has spent more than 20 years in the cell therapy and biopharma industry, including roles at Juno/Celgene and Biogen. Justin earned a BS from University of California at Berkeley and PhD from M.I.T. in Chemical Engineering.